Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.

Over the 8-day study, data from 10 participants receiving a single weekly injection of Zepbound® and 9 participants taking daily DehydraTECH-tirzepatide capsules were collected. Although injected ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...